1. Pink Sheet

Sen. Burr Worries Rising User Fees Helping US FDA Evade Congressional Oversight

 
• By Derrick Gingery

Burr wants more FDA accountability in the new user fee agreements and questions whether they benefit patients. Generic approval modifications get attention at hearing.

Sen. Richard Burr screenshot
Sen. Richard Burr, R-N.C., wants more FDA accountability in its user fee programs. • Source: Screenshot

Outgoing Sen. Richard Burr, R-N.C., continues to warn that the US Food and Drug Administration’s user fee revenue is increasing without the necessary accountability.

Burr ran through a long list of prescription drug, generic drug, biosimilar and device user fee commitments that the FDA has missed during a 5 April Senate Health, Education, Labor and Pensions Committee hearing on the program reauthorizations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

More from Pathways & Standards